Skip to Content
Merck
CN

D-048

N-Desmethylclozapine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C17H17ClN4
CAS Number:
6104-71-8
Molecular Weight:
312.80
UNSPSC Code:
41116107
MDL number:
MFCD00210189
NACRES:
NA.24
EC Number:
200-659-6

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

N-Desmethylclozapine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

InChI key

JNNOSTQEZICQQP-UHFFFAOYSA-N

InChI

1S/C17H17ClN4/c18-12-5-6-15-16(11-12)21-17(22-9-7-19-8-10-22)13-3-1-2-4-14(13)20-15/h1-6,11,19-20H,7-10H2

SMILES string

Clc1ccc2Nc3ccccc3C(=Nc2c1)N4CCNCC4

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

shipped in

wet ice

storage temp.

−20°C

Quality Level

300

Related Categories

General description

N-Desmethylclozapine is an active metabolite of Clozapine, an atypical antipsychotic drug used for treatment of schizophrenia. Clozapine is sold under the trade names Clozaril® and FrazaClo in the US. This Certified Snap-N-Spike® Solution is suitable for use in urine drug testing, clinical toxicology, forensic analysis, and clinical monitoring by LC-MS/MS or GC/MS.

Other Notes

2024 CiteAb Award Winner for Supplier Succeeding in Parkinson′s Research

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Clozaril is a registered trademark of Sandoz, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Regulatory Information

危险化学品
This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yousheng Cai et al.
Scientific reports, 10(1), 10444-10444 (2020-06-28)
Parkinson's disease (PD) is a common dyskinesia disease, the mitochondrial unfolded protein response (mtUPR) may be directly or indirectly involved in the occurrence and development of PD, although the exact mechanism is unclear. We established a dopaminergic neuronal-like cell model
Ariane Wohlfarth et al.
Analytical and bioanalytical chemistry, 400(3), 737-746 (2011-03-12)
An LC-MS/MS method for the determination of the atypic neuroleptic clozapine and its two main metabolites norclozapine and clozapine-N-oxide has been developed and validated for serum and urine. After addition of d4-clozapine as deuterated internal standard a fast single-step liquid-liquid
Tania Godoy et al.
European journal of oral sciences, 119(4), 275-281 (2011-07-06)
Many drugs (e.g. amisulpride) have been used to treat troublesome clozapine-induced salivation; however, varying success has been achieved in this respect, probably because, until recently, the salivatory action of clozapine has been largely unexplained. In the rat, clozapine and its
Thomas I F H Cremers et al.
Drug metabolism and disposition: the biological fate of chemicals, 40(10), 1909-1916 (2012-06-28)
A significant barrier to realization of the full potential of clozapine as a therapeutic agent in the treatment of schizophrenia is the substantial interpatient variability that exists along the therapeutic continuum of no response-efficacious response-adverse response. Genetic polymorphisms that manifest
Jelveh Lameh et al.
Pharmacology & therapeutics, 115(2), 223-231 (2007-06-23)
Currently available treatments for schizophrenia have limited efficacy and are generally poorly tolerated. However, among these antipsychotic agents, clozapine stands apart in having generally superior motoric tolerability and efficacy. One intriguing possibility, based on clinical correlations, receptor activity profiles and
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service